Oncopeptides says a second look at its data offers a win in head-to-head cancer trial — but key OS flop triggers a hold

Sweden’s Oncopeptides has some good news and some bad news to report today.

The good news is the independent review group overseeing a head-to-head study …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On­copep­tides says a sec­ond look at its da­ta of­fers a win in head-to-head can­cer tri­al — but key OS flop trig­gers a hold